K D Crew1, K A Ho1, P Brown2, H Greenlee1, T B Bevers2, B Arun2, N Sneige2, C Hudis3, H L McArthur3, J Chang4, M Rimawi5, T L Cornelison6, J Cardelli7, R M Santella1, A Wang1, S M Lippman8, D L Hershman1. 1. Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA. 2. University of Texas, MD Anderson Cancer Center, Houston, TX, USA. 3. Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 4. The Methodist Hospital Cancer Center, Houston, TX, USA. 5. Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA. 6. Divison of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA. 7. Louisiana State University Health Sciences Center, Shreveport, LA, USA. 8. University of California San Diego Moores Cancer Center, San Diego, CA, USA.
Abstract
BACKGROUND: Observational and experimental data support a potential breast cancer chemopreventive effect of green tea. METHODS: We conducted an ancillary study using archived blood/urine from a phase IB randomised, placebo-controlled dose escalation trial of an oral green tea extract, Polyphenon E (Poly E), in breast cancer patients. Using an adaptive trial design, women with stageI-III breast cancer who completed adjuvant treatment were randomised to Poly E 400 mg (n = 16), 600 mg (n = 11) and 800 mg (n = 3) twice daily or matching placebo (n = 10) for 6 months. Blood and urine collection occurred at baseline, and at 2, 4 and 6 months. Biological endpoints included growth factor [serum hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF)], lipid (serum cholesterol, triglycerides), oxidative damage and inflammatory biomarkers. RESULTS:From July 2007-August 2009, 40 women were enrolled and 34 (26 Poly E, eightplacebo) were evaluable for biomarker endpoints. At 2 months, the Poly E group (all dose levels combined) compared to placebo had a significant decrease in mean serum HGF levels (-12.7% versus +6.3%, P = 0.04). This trend persisted at 4 and 6 months but was no longer statistically significant. For the Poly E group, serum VEGF decreased by 11.5% at 2 months (P = 0.02) and 13.9% at 4 months (P = 0.05) but did not differ compared to placebo. At 2 months, there was a trend toward a decrease in serum cholesterol with Poly E (P = 0.08). No significant differences were observed for other biomarkers. CONCLUSIONS: Our findings suggest potential mechanistic actions of tea polyphenols in growth factor signalling, angiogenesis and lipid metabolism.
RCT Entities:
BACKGROUND: Observational and experimental data support a potential breast cancer chemopreventive effect of green tea. METHODS: We conducted an ancillary study using archived blood/urine from a phase IB randomised, placebo-controlled dose escalation trial of an oral green tea extract, Polyphenon E (Poly E), in breast cancerpatients. Using an adaptive trial design, women with stage I-III breast cancer who completed adjuvant treatment were randomised to Poly E 400 mg (n = 16), 600 mg (n = 11) and 800 mg (n = 3) twice daily or matching placebo (n = 10) for 6 months. Blood and urine collection occurred at baseline, and at 2, 4 and 6 months. Biological endpoints included growth factor [serum hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF)], lipid (serum cholesterol, triglycerides), oxidative damage and inflammatory biomarkers. RESULTS: From July 2007-August 2009, 40 women were enrolled and 34 (26 Poly E, eight placebo) were evaluable for biomarker endpoints. At 2 months, the Poly E group (all dose levels combined) compared to placebo had a significant decrease in mean serum HGF levels (-12.7% versus +6.3%, P = 0.04). This trend persisted at 4 and 6 months but was no longer statistically significant. For the Poly E group, serum VEGF decreased by 11.5% at 2 months (P = 0.02) and 13.9% at 4 months (P = 0.05) but did not differ compared to placebo. At 2 months, there was a trend toward a decrease in serum cholesterol with Poly E (P = 0.08). No significant differences were observed for other biomarkers. CONCLUSIONS: Our findings suggest potential mechanistic actions of teapolyphenols in growth factor signalling, angiogenesis and lipid metabolism.
Authors: Maki Inoue-Choi; Jian-Min Yuan; Chung S Yang; David J Van Den Berg; Mao-Jung Lee; Yu-Tang Gao; Mimi C Yu Journal: Int J Mol Epidemiol Genet Date: 2010
Authors: Katherine D Crew; Powel Brown; Heather Greenlee; Therese B Bevers; Banu Arun; Clifford Hudis; Heather L McArthur; Jenny Chang; Mothaffar Rimawi; Lana Vornik; Terri L Cornelison; Antai Wang; Hanina Hibshoosh; Aqeel Ahmed; Mary Beth Terry; Regina M Santella; Scott M Lippman; Dawn L Hershman Journal: Cancer Prev Res (Phila) Date: 2012-07-24
Authors: Kanwal P Raghav; Wenting Wang; Shuying Liu; Mariana Chavez-MacGregor; Xiaolong Meng; Gabriel N Hortobagyi; Gordon B Mills; Funda Meric-Bernstam; George R Blumenschein; Ana M Gonzalez-Angulo Journal: Clin Cancer Res Date: 2012-02-28 Impact factor: 12.531
Authors: N R Stendell-Hollis; C A Thomson; P A Thompson; J W Bea; E C Cussler; I A Hakim Journal: J Hum Nutr Diet Date: 2010-08-27 Impact factor: 3.089
Authors: Jie Liao; Guang-Yu Yang; Eon Sub Park; Xiaofeng Meng; Yuhai Sun; Dongxuan Jia; Darren N Seril; Chung S Yang Journal: Nutr Cancer Date: 2004 Impact factor: 2.900
Authors: Sze Wan Hung; Yiran Li; Xiaoyan Chen; Kai On Chu; Yiwei Zhao; Yingyu Liu; Xi Guo; Gene Chi-Wai Man; Chi Chiu Wang Journal: Front Pharmacol Date: 2022-07-04 Impact factor: 5.988
Authors: Felicia Carotenuto; Maria C Albertini; Dario Coletti; Alessandra Vilmercati; Luigi Campanella; Zbigniew Darzynkiewicz; Laura Teodori Journal: Int J Mol Sci Date: 2016-05-19 Impact factor: 5.923